{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T05:14:21Z","timestamp":1785647661462,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1006\/cyto.2002.2012","type":"journal-article","created":{"date-parts":[[2003,3,14]],"date-time":"2003-03-14T12:12:07Z","timestamp":1047643927000},"page":"304-311","source":"Crossref","is-referenced-by-count":113,"title":["ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE"],"prefix":"10.1006","volume":"20","author":[{"given":"Asao","family":"Katsume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamitsu","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ohsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/cyto.2002.2012_RF1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Advances in Immunol"},{"key":"10.1006\/cyto.2002.2012_RF2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"10.1006\/cyto.2002.2012_RF3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice","volume":"86","author":"Brant","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1006\/cyto.2002.2012_RF4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1006\/cyto.2002.2012_RF5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1006\/cyto.2002.2012_RF6","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.4049\/jimmunol.143.12.3949","article-title":"Involvement of IL-6 in mesangial proliferative glomerulonephritis","volume":"143","author":"Horii","year":"1989","journal-title":"J Immunol"},{"key":"10.1006\/cyto.2002.2012_RF7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/ki.1990.193","article-title":"Interleukin 6 is an autocrine growth factor for mesangial cell","volume":"38","author":"Ruef","year":"1990","journal-title":"Kidney Int"},{"key":"10.1006\/cyto.2002.2012_RF8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1084\/jem.165.3.914","article-title":"Identification of the human 26-kD protein, interferon b2, as a cell hybridoma\/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor","volume":"165","author":"Van Damme","year":"1987","journal-title":"J Exp Med"},{"key":"10.1006\/cyto.2002.2012_RF9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"10.1006\/cyto.2002.2012_RF10","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V74.5.1704.1704","article-title":"Increased plasma levels of interleukin-6 in sepsis","volume":"74","author":"Hack","year":"1989","journal-title":"Blood"},{"key":"10.1006\/cyto.2002.2012_RF11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.169.1.333","article-title":"The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1 and fatal outcome","volume":"169","author":"Waage","year":"1989","journal-title":"J Exp Med"},{"key":"10.1006\/cyto.2002.2012_RF12","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1210\/endo-128-5-2657","article-title":"Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice","volume":"128","author":"Black","year":"1991","journal-title":"Endocrinology"},{"key":"10.1006\/cyto.2002.2012_RF13","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1172\/JCI115767","article-title":"Evidence for the involvement of interleukin 6 in experimental cancer cachexia","volume":"89","author":"Strassmann","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1006\/cyto.2002.2012_RF14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody","volume":"330","author":"Beck","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1006\/cyto.2002.2012_RF15","first-page":"259","article-title":"Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody","volume":"20","author":"Wendling","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1006\/cyto.2002.2012_RF16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy","volume":"95","author":"Nishimoto","year":"2000","journal-title":"Blood"},{"key":"10.1006\/cyto.2002.2012_RF17","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","article-title":"IgG1 plasmacytosis in interleukin 6 transgenic mice","volume":"86","author":"Suematsu","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1006\/cyto.2002.2012_RF18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/clin.1996.4278","article-title":"Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice","volume":"82","author":"Katsume","year":"1997","journal-title":"Clin Immuno Immunopathol"},{"key":"10.1006\/cyto.2002.2012_RF19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/bbrc.1995.1168","article-title":"Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse","volume":"207","author":"Tsujinaka","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1006\/cyto.2002.2012_RF20","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","article-title":"Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6","volume":"90","author":"Tamura","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1006\/cyto.2002.2012_RF21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/eji.1830180618","article-title":"Establishment of an interleukin 6 (IL6)\/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies","volume":"18","author":"Matsuda","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1006\/cyto.2002.2012_RF22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1172\/JCI118398","article-title":"Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice","volume":"97","author":"Tsujinaka","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1006\/cyto.2002.2012_RF23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"key":"10.1006\/cyto.2002.2012_RF24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1084\/jem.167.2.332","article-title":"The essential role of B cell stimulatory factor 2 (BSF-2\/IL-6) for the terminal differentiation of B cells","volume":"167","author":"Muraguchi","year":"1988","journal-title":"J Exp Med"},{"key":"10.1006\/cyto.2002.2012_RF25","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.4049\/jimmunol.140.9.3040","article-title":"Stimulation of murine hemopoietic colony formation by human IL-6","volume":"140","author":"Wong","year":"1988","journal-title":"J Immunol"},{"key":"10.1006\/cyto.2002.2012_RF26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood.V73.1.108.108","article-title":"In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs","volume":"73","author":"Ulich","year":"1989","journal-title":"Blood"},{"key":"10.1006\/cyto.2002.2012_RF27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V73.3.666.666","article-title":"Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF","volume":"73","author":"Caracciolo","year":"1989","journal-title":"Blood"},{"key":"10.1006\/cyto.2002.2012_RF28","first-page":"2885","article-title":"Interleukin 6 perfusion stimulates reconstitution of the immune, and hematopoietic systems after 5-fluorouracil treatment","volume":"50","author":"Takatsuki","year":"1990","journal-title":"Cancer Res"},{"key":"10.1006\/cyto.2002.2012_RF29","first-page":"1682","article-title":"Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice","volume":"147","author":"Kitamura","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1006\/cyto.2002.2012_RF30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/369571a0","article-title":"cMpl ligand is a humoral regulator of megakaryocytopoiesis","volume":"369","author":"Wendling","year":"1994","journal-title":"Nature"},{"key":"10.1006\/cyto.2002.2012_RF31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/369568a0","article-title":"Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin","volume":"369","author":"Kaushansky","year":"1994","journal-title":"Nature"},{"key":"10.1006\/cyto.2002.2012_RF32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature"},{"key":"10.1006\/cyto.2002.2012_RF33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/j.1460-2075.1986.tb04297.x","article-title":"Purification and characterization of human granulocyte colony-stimulating factor (G-CSF)","volume":"5","author":"Nomura","year":"1986","journal-title":"EMBO J"},{"key":"10.1006\/cyto.2002.2012_RF34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/(SICI)1097-0215(19961127)68:5<637::AID-IJC14>3.0.CO;2-Z","article-title":"Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways","volume":"68","author":"Fujita","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1006\/cyto.2002.2012_RF35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hep.1840160320","article-title":"Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines","volume":"16","author":"Kowalski-Saunders","year":"1992","journal-title":"Hepatology"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466602920120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466602920120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T21:51:02Z","timestamp":1704750662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466602920120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S1043466602920120"],"URL":"https:\/\/doi.org\/10.1006\/cyto.2002.2012","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}